BJDX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.1M
-12.2%
2.3M
+21.2%
1.9M
+32.6%
1.5M
-9.6%
1.6M
R&D
1.1M
-22.3%
1.4M
+77.1%
811.8K
+38.5%
586.1K
-25.4%
785.6K
SG&A
944.8K
+3.7%
911.3K
-19.1%
1.1M
+28.7%
875.6K
+5.3%
831.3K
Operating Income
-2061413
+12.2%
-2349124
-21.2%
-1938831
-32.6%
-1461747
+9.6%
-1616947
EBITDA
-1999491
+13.8%
-2320931
-21.4%
-1911068
-33.2%
-1434332
+10.7%
-1606323
Net Income
-2011843
+13.4%
-2324013
-21.1%
-1919241
-34.2%
-1429812
+10.5%
-1597632
EPS (Basic)
$-1.72
+61.6%
$-4.48
+42.6%
$-7.80
-27.2%
$-6.13
+63.8%
$-16.92
EPS (Diluted)
$-1.72
+61.6%
$-4.48
+42.6%
$-7.80
-27.2%
$-6.13
+63.8%
$-16.92
Shares (Diluted)
1.2M
+125.6%
519.8K
+111.2%
246.2K
+5.5%
233.3K
+147.1%
94.4K
Bluejay Diagnostics (BJDX) — Financials